Century Therapeutics, INC

Century Therapeutics stockholders approved an increase in authorized common stock from 300 million to 450 million shares at the 2026 Annual Meeting.

Century Therapeutics announced new preclinical data for its iPSC-derived cell therapy, CNTY-813, demonstrating durable glucose control and immune evasion, advancing its potential as a functional cure for Type 1 Diabetes.

Century Therapeutics reported Q1 2026 financial results, highlighting progress in its type 1 diabetes and cancer cell therapies, with a cash runway extending into Q1 2029.

Century Therapeutics, Inc. filed a prospectus supplement for its existing at-the-market equity offering program, with $131.6 million remaining available for sale.

Century Therapeutics significantly reduced its net loss and extended its cash runway into 2029, driven by increased collaboration revenue and a successful $135 million private placement.

Century Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum bid price rule, leading to the decision not to proceed with a previously approved reverse stock split.

Century Therapeutics reports a significant drop in collaboration revenue and continued operating losses in its Q1 2026 filing, while highlighting progress in its iPSC cell therapy pipeline.

Century Therapeutics reports a nine-month net income driven by a collaboration termination, extends its cash runway into Q4 2027, and reprioritizes its cell therapy pipeline.

Century Therapeutics reported a significant net income increase driven by a collaboration termination, while discontinuing a key lymphoma program and implementing a 51% workforce reduction to prioritize autoimmune and preclinical programs.

Century Therapeutics' Q1 2025 results show a significant net income increase due to the termination of the Bristol-Myers Squibb collaboration agreement.

Century Therapeutics reports its third quarter 2024 financial results, detailing progress in clinical trials, strategic pipeline expansion, and a strengthened financial position.

Century Therapeutics reported its second quarter 2024 financial results, highlighting progress in clinical trials and strategic acquisitions.

Century Therapeutics reported a significant reduction in net loss for 2025, driven by collaboration revenue, and extended its cash runway into Q1 2029 with a recent private placement, while reprioritizing its cell therapy pipeline.

Century Therapeutics reports its 2024 financial results and outlines a strategic shift in its preclinical pipeline, focusing on iT cell therapies.

Century Therapeutics and Fujifilm Cellular Dynamics have entered into a new licensing agreement expanding their collaboration to include autoimmune and inflammatory diseases, alongside amendments to existing agreements.

Chief Technology and Manufacturing Officer Gregory Russotti sold 2,584 shares of Century Therapeutics to cover tax obligations.

SVP of Finance & Operations Douglas Carr sold 1,654 shares of Century Therapeutics to cover tax withholding obligations.

CEO Brent Pfeiffenberger disposed of 13,849 shares of Century Therapeutics to satisfy tax obligations related to RSU vesting.

Chief Scientific Officer Chad Cowan reported the withholding of 358 shares to satisfy tax obligations upon RSU vesting.

Director Alessandro Riva was granted 74,000 stock options in Century Therapeutics, Inc. (IPSC) on June 11, 2026.

Director Daphne Quimi was granted 74,000 stock options in Century Therapeutics, Inc. as part of an equity incentive.

Century Therapeutics has filed its 2026 proxy statement, outlining director elections, auditor ratification, and a proposal to increase authorized common stock.

Century Therapeutics, Inc. will hold a special meeting on January 22, 2026, to vote on a reverse stock split ranging from 1-for-5 to 1-for-30.

Century Therapeutics, Inc. is calling a Special Meeting of Stockholders on January 22, 2026, to vote on a reverse stock split to maintain its Nasdaq listing.

Century Therapeutics will hold its annual stockholder meeting on June 12, 2025, to elect Class I directors and ratify the appointment of Ernst & Young LLP as its independent auditor.

Century Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 12, 2025, to vote on director elections and the ratification of its accounting firm.

Century Therapeutics is holding its annual meeting on June 20, 2024, seeking shareholder votes on key proposals including director elections, auditor ratification, and an amendment to limit officer liability.

Point72 Asset Management and Steven A. Cohen have reported a 3.3% beneficial ownership stake in Century Therapeutics, Inc.

RTW Investments, LP and Roderick Wong have reported a beneficial ownership of 7.1% in Century Therapeutics, Inc. common stock.

RA Capital Management and its affiliates have reported a 9.9% beneficial ownership stake in Century Therapeutics, Inc., following a recent private placement.

A group of Venrock entities and individuals has reported a 7.1% beneficial ownership stake in Century Therapeutics, Inc., primarily through common stock and warrants acquired in a recent private placement.

Commodore Capital LP and its affiliates have reported a 7.1% beneficial ownership stake in Century Therapeutics, Inc., including shares and warrants.

TCG Crossover Funds II and III, along with Chen Yu, have reported a combined beneficial ownership of 9.9% in Century Therapeutics, Inc. common stock.